

# Iole Macchia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4249122/publications.pdf>

Version: 2024-02-01

27  
papers

989  
citations

516561  
16  
h-index

526166  
27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1449  
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. <i>Oncolimmunology</i> , 2017, 6, e1317420.	2.1	137
2	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). <i>Vaccine</i> , 2001, 19, 2862-2877.	1.7	135
3	Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. <i>Cancer Research</i> , 2011, 71, 3528-3539.	0.4	72
4	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004, 22, 3258-3269.	1.7	70
5	HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection. <i>Journal of Immunology</i> , 2009, 182, 2888-2897.	0.4	65
6	Combining Type I Interferons and 5-Aza-2'-Deoxycytidine to Improve Anti-Tumor Response against Melanoma. <i>Journal of Investigative Dermatology</i> , 2017, 137, 159-169.	0.3	60
7	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. <i>PLoS ONE</i> , 2012, 7, e48781.	1.1	56
8	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. <i>Journal of Medical Primatology</i> , 2003, 29, 193-208.	0.3	51
9	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139.	1.8	36
10	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. <i>DNA and Cell Biology</i> , 2002, 21, 599-610.	0.9	35
11	Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	33
12	Transduction of Human Antigen-Presenting Cells with Integrase-Defective Lentiviral Vector Enables Functional Expansion of Primed Antigen-Specific CD8 <sup>+</sup> T Cells. <i>Human Gene Therapy</i> , 2010, 21, 1029-1035.	1.4	32
13	Expression of CD8 $\alpha$ identifies a distinct subset of effector memory CD4 <sup>+</sup> T lymphocytes. <i>Immunology</i> , 2006, 119, 232-242.	2.0	26
14	Long-Lasting Protection by Live Attenuated Simian Immunodeficiency Virus in Cynomolgus Monkeys: No Detection of Reactivation after Stimulation with a Recall Antigen. <i>Virology</i> , 1999, 256, 291-302.	1.1	25
15	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P <sub>cy243</sub> . <i>Viral Immunology</i> , 2009, 22, 117-124.	0.6	18
16	Lenalidomide improves the therapeutic effect of an interferon- $\gamma$ -dendritic cell-based lymphoma vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1791-1804.	2.0	18
17	Increased replication of sendai virus in morphine-treated epithelial cells: evidence for the involvement of the intracellular levels of glutathione. <i>International Journal of Immunopharmacology</i> , 1999, 21, 185-193.	1.1	17
18	Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. <i>Journal of Medical Primatology</i> , 2007, 36, 180-194.	0.3	17

#	ARTICLE	IF	CITATIONS
19	Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIVmacJ5 on the kinetics of SIV replication in cynomolgus monkeys. Journal of Medical Primatology, 2001, 30, 197-206.	0.3	15
20	Innovative Approaches to Develop Prophylactic and Therapeutic Vaccines against HIV/AIDS. Advances in Experimental Medicine and Biology, 2009, 655, 189-242.	0.8	13
21	Mechanisms of Action of Ozone Therapy in Emerging Viral Diseases: Immunomodulatory Effects and Therapeutic Advantages With Reference to SARS-CoV-2. Frontiers in Microbiology, 2022, 13, 871645.	1.5	13
22	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. Journal of General Virology, 2006, 87, 3385-3392.	1.3	11
23	Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. Medical Science Monitor, 2006, 12, BR330-40.	0.5	9
24	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. Cells, 2020, 9, 940.	1.8	8
25	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Na <sup>+</sup> ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	8
26	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Frontiers in Oncology, 2020, 10, 202.	1.3	6
27	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. Virus Research, 2007, 126, 86-95.	1.1	3